Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 13:55:00 -0500

LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma, Ltd., (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that bought securities between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”). Quantum investors have until February 23, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 13:55:00 -0500

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 13:55:00 -0500

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via

Portnoy Law Firm Announces Class Action on Behalf of Quantum Biopharma, Ltd. Investors

Tue, 17 Feb 2026 13:55:00 -0500

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Tue, 17 Feb 2026 09:41:00 -0500

LOS ANGELES, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Quantum Biopharma Ltd. (“Quantum” or the "Company") (NASDAQ: QNTM) investors of a class action on behalf of investors that bought securities between January 6, 2021 and October 15, 2025, inclusive (the “Class Period”). Quantum investors have until February 23, 2026 to file a lead plaintiff motion.

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Tue, 17 Feb 2026 09:41:00 -0500

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Tue, 17 Feb 2026 09:41:00 -0500

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the

Portnoy Law Firm Announces Class Action on Behalf of Quantum Corporation Investors

Tue, 17 Feb 2026 09:41:00 -0500

Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 844-767-8529 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the

Form SCHEDULE 13G/A Quantum Biopharma Ltd. Filed by: Malone Wealth Ventures LLC

Tue, 03 Feb 2026 09:20:00 -0500

si-local-file:///var/storage/secattach/20260203/25935634.html

Form SCHEDULE 13G/A Quantum Biopharma Ltd. Filed by: Malone Wealth Ventures LLC

Tue, 03 Feb 2026 09:20:00 -0500

si-local-file:///var/storage/secattach/20260203/25935634.html

Form SCHEDULE 13G/A Quantum Biopharma Ltd. Filed by: Malone Wealth Ventures LLC

Tue, 03 Feb 2026 09:20:00 -0500

si-local-file:///var/storage/secattach/20260203/25935634.html

Quantum BioPharma completes dosing in toxicity studies for MS drug

Tue, 23 Dec 2025 08:02:44 -0500

Quantum BioPharma Ltd. (NASDAQ: QNTM) announced it has completed oral dosing in 180-day toxicity and toxicokinetic studies for its drug candidate Lucid-21-302, designed to treat multiple sclerosis.

The studies will support the company's Investigational New Drug application with the US Food and Drug Administration and help design a Phase 2 trial for the treatment in people with multiple sclerosis, according to a company statement.

"We are very pleased that dosing is now complete in both 180-day chronic toxicity studies. These studies allow us to advance the Lucid-MS drug development program as they are critical components to the IND application with the FDA,"

Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS)